Answer: Poisoned Barn Owls can die slowly or live with a poison remnant in their body, according to research. After eating three mice carrying the toxin Brodifacoum, a Barn Owl usually dies in 6 to 17 days.
Mangroves<span> provide a number valuable </span>ecosystem services<span> that contribute to human well being including provisioning, regulating ,and habitat.
</span>
Answer:
The type of regulation of gene expression that would have the greatest chance of success is Posttranslational control (E).
Explanation:
The defect is found on the structure of the protein, this means that the process of formation of the protein and the codons responsible for each amino acid in the protein is in correct order, this set the transcriptional and translational process aside as being correct.
Therefore, the problem lies in the formation of secondary or tertiary structure of the protein which requires a good number of proteins also, wherein lies tha main problem in the cell membrane protein. Thus the regulation of the posttranslational process and correction of the proteins needed at this stage will give the best chance of success.
Answer:
c) Archaea
Explanation:
Los dominios biológicos son los taxones de más alto nivel, por encima de los reinos y abarcando todos los taxones, caracterizándolos de la manera más generalizada posible, dentro de la clasificación científica. Hay tres tipos de dominios llamados Archaea, Bacteria y Eukarya. Entre ellos, el dominio conocido como Archaea es el que engloba a los organismos procarióticos, unicelulares y patógenos, es decir, capaces de provocar enfermedades en el ser humano.
Answer:
Explanation:
The more similar the two species are, the more their niche overlaps and the more competition there is.
<em>The most interesting results obtained in animal models of passive immunotherapies developed according to the “amyloid-beta cascade hypothesis” and the “Tau hypothesis” are monoclonal antibodies that directly or indirectly target Aβ plaques or neurofibrillary tangles. Unfortunately, these therapeutic antibodies cannot replicate their promising effects on humans at the clinical phase. Despite this, we still hope to learn from these failures and to explore new pathways. The great effects obtained in animals with passive immunotherapy suggest that this technology may be an important key to curative treatment. The remaining challenge is to find a way to achieve the same encouraging results for humans. Alzheimacy expects to join hands with global partners to focus on the development of therapeutic antibodies for Alzheimer’s disease (AD) and continue to fight against this disease.</em>
<em>https://www.creativebiomart.net/alzheimacy/therapeutics/therapeutic-antibody/</em>
